drugset / Trial / NCT05612581
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
Timeline
- Start
- 2023-05-10
- Primary completion
- 2024-10-15
- Completion
- 2025-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Tobevibart | Monoclonal antibody | — | Subcutaneous |
| Subject | VIR-2218 | Small interfering RNA (siRNA) | — | Subcutaneous |
| Background | TDF | Unknown | — | Oral |